Related references
Note: Only part of the references are listed.Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy
Florentia Peintinger et al.
MODERN PATHOLOGY (2015)
Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy
A. Sheri et al.
ANNALS OF ONCOLOGY (2015)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients
A. Romero et al.
ANNALS OF ONCOLOGY (2013)
Pathologic Response and Long-Term Follow-up in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy A Comparison Between Classifications and Their Practical Application
Adriana D. Corben et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2013)
Mitotic counts in breast cancer after neoadjuvant systemic chemotherapy and development of metastatic disease
Janice Diaz et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial
E. Provenzano et al.
BRITISH JOURNAL OF CANCER (2013)
Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer
Gunter von Minckwitz et al.
CLINICAL CANCER RESEARCH (2013)
Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer The ACOSOG Z1071 (Alliance) Clinical Trial
Judy C. Boughey et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
An International Ki67 Reproducibility Study
Mei-Yin C. Polley et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study
Thorsten Kuehn et al.
LANCET ONCOLOGY (2013)
Change in HER2 (ERBB2) gene status after taxane-based chemotherapy for breast cancer: polyploidization can lead to diagnostic pitfalls with potential impact for clinical management
Alexander Valent et al.
CANCER GENETICS (2013)
Prognostic Value of a Positive-to-negative Change in Hormone Receptor Status after Neoadjuvant Chemotherapy in Patients with Hormone Receptor-positive Breast Cancer
Sheng Chen et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40)
Gunter von Minckwitz et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Variability in hormone and growth factor receptor expression in primary versus recurrent, metastatic, and post-neoadjuvant breast carcinoma
Mark N. Jabbour et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27
Eleftherios P. Mamounas et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The Value of Combined Large Format Histopathology Technique to Assess the Surgically Removed Breast Tissue following Neoadjuvant Chemotherapy: A Single Institution Study of 40 Cases
Julio A. Ibarra
INTERNATIONAL JOURNAL OF BREAST CANCER (2012)
A Novel Automated Assay for the Rapid Identification of Metastatic Breast Carcinoma in Sentinel Lymph Nodes
Sheldon Feldman et al.
CANCER (2011)
The Hormonal Receptor Status in Breast Cancer can be Altered by Neoadjuvant Chemotherapy: A Meta-Analysis
Ning Zhang et al.
CANCER INVESTIGATION (2011)
Accelerating Identification and Regulatory Approval of Investigational Cancer Drugs
Laura J. Esserman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Validation of a Novel Staging System for Disease-Specific Survival in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy
Elizabeth A. Mittendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
Mitch Dowsett et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types
Sherene Loi et al.
LANCET ONCOLOGY (2011)
Number of Lymph Nodes Identified at Axillary Dissection Effect of Neoadjuvant Chemotherapy and Other Factors
Judy C. Boughey et al.
CANCER (2010)
Pure and Predominantly Pure Intralymphatic Breast Carcinoma After Neoadjuvant Chemotherapy An Unusual and Adverse Pattern of Residual Disease
Joseph T. Rabban et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2009)
The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer
Robin L. Jones et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer
T. Hirata et al.
BRITISH JOURNAL OF CANCER (2009)
Prognostic Significance of Occult Axillary Lymph Node Metastases After Chemotherapy-induced Pathologic Complete Response of Cytologically Proven Axillary Lymph Node Metastases From Breast Cancer
Asif Loya et al.
CANCER (2009)
Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes
Elizabeth A. Mittendorf et al.
CLINICAL CANCER RESEARCH (2009)
A new prognostic classification after primary chemotherapy for breast cancer: Residual disease in breast and nodes (RDBN)
Philippe Chollet et al.
CANCER JOURNAL (2008)
Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer
Frederique Penault-Llorca et al.
HUMAN PATHOLOGY (2008)
Recommendations for Collection and Handling of Specimens From Group Breast Cancer Clinical Trials
Brian R. Leyland-Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
Priya Rastogi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Neoadjuvant chemotherapy in invasive breast cancer results in a lower axillary lymph node count
Julie Belanger et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2008)
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics
Matthew J. Ellis et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Changes and Predictive and Prognostic Value of the Mitotic Index, Ki-67, Cyclin D1, and Cyclo-oxygenase-2 in 710 Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Frederique Penault-Llorca et al.
ONCOLOGIST (2008)
American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer
Lyndsay Harris et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
[Anonymous]
JOURNAL OF ONCOLOGY PRACTICE (2007)
Measurement of residual breast cancer burden to predict survival after Neoadjuvant chemotherapy
W. Fraser Symmans et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer
M. Colleoni et al.
ANNALS OF ONCOLOGY (2007)
Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome
Chafika Mazouni et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy
S. E. Pinder et al.
HISTOPATHOLOGY (2007)
Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy
Olivier Tacca et al.
ONCOLOGIST (2007)
Axillary lymph node count is lower after neoadjuvant chemotherapy
Heather Neuman et al.
AMERICAN JOURNAL OF SURGERY (2006)
How do we measure a residual size in Histopthology (the gold standard) after neoadjuvant chemotherapy?
S. K. Apple et al.
BREAST (2006)
Size of residual lymph node metastasis after neoadjuvant chemotherapy in locally advanced breast cancer patients is prognostic
N Klauber-DeMore et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy
BT Hennessy et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
American joint committee on cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome
LA Carey et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response
R Rajan et al.
CANCER (2004)
Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer
V Diéras et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer?
P Chollet et al.
BRITISH JOURNAL OF CANCER (2003)
A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival
KN Ogston et al.
BREAST (2003)
Histopathologic evidence of tumor regression in the axillary lymph nodes of patients treated with preoperative chemotherapy correlates with breast cancer outcome
LA Newman et al.
ANNALS OF SURGICAL ONCOLOGY (2003)
Pathobiology of preoperative chemotherapy - Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-18
ER Fisher et al.
CANCER (2002)
Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation
TA Buchholz et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes
R Rouzier et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Axillary lymph node scarring and the association with tumour response following neoadjuvant chemoendocrine therapy for breast cancer
J Donnelly et al.
BREAST (2001)
Share Paper
